CTSO
Cytosorbents Corp
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Cytosorbents has 4 disclosed suppliers and 4 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Cytosorbents Corp
4.55
SentenceAvenue Capital Group agreed to loan the Company up to an aggregate of $20 million (the "Avenue Capital Commitment"), to be disbursed in two tranches.
CTSO 10-Kaccession 0001104659-26-036451
SentenceThe proceeds from the Avenue Capital Commitment were used to pay off the existing outstanding debt with Bridge Bank and were additionally used for working capital purposes and to fund general business requirements.
CTSO 10-Kaccession 0001104659-26-036451
SentenceWe previously engaged in discussions with the Brotech Corporation and its affiliate, Purolite International, Inc. (collectively referred to as "Purolite"), which had demonstrated a strong interest in being our polymer manufacturer.
CTSO 10-Kaccession 0001104659-26-036451
SentenceWe previously engaged in discussions with the Brotech Corporation and its affiliate, Purolite International, Inc. (collectively referred to as "Purolite"), which had demonstrated a strong interest in being our polymer manufacturer.
CTSO 10-Kaccession 0001104659-26-036451
SentenceIn 2015, we entered into a distribution agreement for CytoSorb with Aferetica s.r.l., a distributor based in Bologna, Italy that specializes in the sale of certain medical products and devices, specifically extracorporeal therapies, in the critical care, cardiac surgery and liver disease markets ("Aferetica").
CTSO 10-Kaccession 0001104659-26-036451
SentenceIn March 2021, we announced the launch of a global co-marketing agreement with B. Braun Avitum AG, one of the world's leading manufacturers of medical devices and pharmaceutical products and services, to promote the use of CytoSorb ® with B. Braun's latest OMNI ® continuous blood purification platform and OMNIset ® Plus bloodline set (set version 3.0 or higher).
CTSO 10-Kaccession 0001104659-26-036451
SentenceThe Company has developed various multi-country distribution and/or co-marketing agreements with Fresneius Medical Care AG dating back to December 2014.
CTSO 10-Kaccession 0001104659-26-036451
SentenceUnder the terms of this amended and restated agreement, Terumo received non-exclusive distribution rights in France to promote and sell the CytoSorb CPB procedure pack for intra-operative use during cardiac surgery at specifically named hospitals in France.
CTSO 10-Kaccession 0001104659-26-036451
Largest filed tie
—
Expected move
No implied move.